CytomX Therapeutics, Inc. (CTMX) stock

CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30

$2.04+0.00 (0.00%)

Close on Nov 13, 2026Market cap $444.52MP/E –Yield –

CytomX Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

CytomX Therapeutics's EV/EBITDA was 22.4× on Jan 30, 2026.

Period	Period end	Value	Change (pts)
2026	Jan 30, 2026	22.4×	+7.2
2025	Dec 31, 2025	15.2×	–

Parsed from the XBRL in CytomX Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CTMX.

Revenue growth-87.7% · median 176.6%

Operating margin-676.5% · median -599.3%

Net margin-609.0% · median -428.7%

Advertisement
300 × 250

See a number that looks wrong?